Top Page
EchoIQ Limited
(Sydney:EIQ)
EchoIQ Limited (EIQ) vs. iShares MSCI Australia ETF (EWA)
EchoIQ Limited Business Overview & Revenue Model
EchoIQ Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 129.91K | 44.50K | 107.33K | 251.10K | 441.98K | 679.87K | Gross Profit |
| -3.69M | -2.88M | -7.01M | -3.19M | -1.75M | -1.10M | EBIT |
| -8.16M | -5.92M | -8.27M | -6.53M | -3.76M | -2.85M | EBITDA |
| -8.18M | -4.81M | -7.07M | -5.85M | -3.14M | -2.54M | Net Income Common Stockholders |
| -8.87M | -5.41M | -8.27M | -5.99M | -2.99M | -2.68M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.35M | 2.12M | 3.28M | 2.41M | 3.81M | 3.48M | Total Assets |
| 10.63M | 8.26M | 10.38M | 10.23M | 10.93M | 4.15M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 43.83K | 43.83K | Net Debt |
| -5.35M | -2.12M | -3.28M | -2.41M | -3.77M | -3.43M | Total Liabilities |
| 628.02K | 1.49M | 3.00M | 2.21M | 1.10M | 1.03M | Stockholders Equity |
| 10.00M | 6.77M | 7.38M | 8.02M | 9.84M | 3.12M |
| Cash Flow | Free Cash Flow | ||||
| -5.30M | -3.92M | -5.28M | -2.95M | -2.43M | -1.19M | Operating Cash Flow |
| -5.30M | -3.92M | -4.94M | -2.58M | -1.43M | -1.10M | Investing Cash Flow |
| -2.90K | 0.00 | -59.81K | -367.33K | -1.00M | -342.80K | Financing Cash Flow |
| 8.88M | 2.77M | 5.88M | 1.55M | 2.77M | 4.21M |
EchoIQ Limited Technical Analysis
EchoIQ Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $11.97B | 10.29 | -7.47% | 2.99% | 7.32% | -8.06% | |
39 Underperform | AU$135.49M | ― | -105.20% | ― | 51.06% | -19.12% | |
| $13.79M | ― | -467.81% | ― | ― | ― | ||
| $52.38M | ― | -9.88% | ― | ― | ― | ||
61 Neutral | AU$17.93M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
53 Neutral | AU$676.58M | ― | -112.97% | ― | ― | -84.82% | |
39 Underperform | AU$2.21M | ― | ― | 55.07% | 88.20% |
EchoIQ Limited Corporate Events
Echo IQ Limited released its quarterly report for the period ending 31 March 2025, highlighting its current corporate structure with 588,521,043 ordinary shares and a shareholder base of 3,465. The top 20 shareholders hold 42.37% of the company. The report underscores Echo IQ’s commitment to leveraging AI technology to improve cardiology outcomes, which positions the company as a significant player in the healthcare technology sector.
Echo IQ Limited has announced its approval to trade on the OTCQB Venture Market in the United States under the ticker code ECHQF, starting 16 April 2025. This move is part of Echo IQ’s strategy to expand its presence in the US market, particularly focusing on the commercialisation of its EchoSolv technology for early detection of structural heart disease. The listing is expected to increase liquidity and provide access to new investor groups, supporting Echo IQ’s ongoing commercialisation efforts and strengthening its partnerships in US capital markets.
Echo IQ has secured a collaboration agreement with the Mayo Clinic Platform to advance a validation study for its heart failure clinical decision support solution, EchoSolv HF. This partnership follows a positive engagement with the FDA, providing a clear path towards regulatory clearance. The validation study, which is the final requirement before FDA submission, will assess EchoSolv HF’s ability to detect various forms of heart failure. The collaboration also includes the potential for licensing EchoSolv HF to 30 Mayo Clinic Care Network sites. With heart failure being a significant health issue in the US, the successful deployment of EchoSolv HF could lead to improved patient outcomes and substantial market opportunities.
Echo IQ has announced strategic partnership and integration agreements with ScImage and MedAxiom to expand the distribution of its EchoSolv AS technology across 36 cardiology networks in the United States. This collaboration will enhance the detection rates of severe aortic stenosis, solidifying Echo IQ’s position as a leader in AI-driven cardiovascular disease detection and expanding its presence in the US market.
Echo IQ has announced the availability of a recording from its recent investor webinar, where CEO Dustin Haines discussed the US commercialization strategy for EchoSolv AS and highlighted key milestones achieved in early 2025. The webinar also covered the company’s clinical development pipeline and upcoming opportunities, providing stakeholders with insights into Echo IQ’s strategic direction and potential growth in the medical technology sector.
EchoIQ Limited has announced a change in the director’s interest, specifically for Mr. Ken Nelson. On March 4, 2025, Mr. Nelson acquired 4,000,000 unlisted options at a value of $0.25 each, as part of a director appointment agreement. This acquisition marks the first holding of such securities by Mr. Nelson, potentially impacting the company’s governance and strategic direction with his increased stake.
EchoIQ Limited has announced the issuance of unquoted equity securities, including performance rights and options, as part of their employee incentive scheme. This move, involving a total of 14 million securities with various expiration dates and exercise prices, is aimed at enhancing employee engagement and aligning interests with the company’s long-term goals.
EchoIQ Limited has announced the issuance of 1,500,000 unquoted options set to expire on March 4, 2028, with an exercise price of $0.35. This move is part of previously announced transactions and is not intended to be quoted on the ASX, reflecting the company’s strategic financial maneuvers to potentially enhance its capital structure.
EchoIQ Limited has announced the issuance of 4,000,000 unquoted securities in the form of options expiring on March 4, 2030, with an exercise price of $0.25. This move is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
EchoIQ Limited has announced the cessation of certain securities, specifically 3,000,000 options that were set to expire on June 14, 2027. This cessation occurred because the conditions for these securities were not met or became incapable of being satisfied, impacting the company’s issued capital structure.
Echo IQ announced an investor webinar scheduled for March 13, 2025, where CEO Dustin Haines will update on the US commercialization strategy for EchoSolv-AS and discuss the company’s clinical development pipeline. This event reflects Echo IQ’s ongoing efforts to strengthen its market position and engage stakeholders in its strategic initiatives.
Echo IQ has made significant strides in its US commercialization strategy for EchoSolv-AS, with its integration at Beth Israel Deaconess Medical Center, a flagship site, and plans to expand to 60 more sites. The company is advancing discussions with larger hospital groups and pursuing a CPT code for reimbursement, which is crucial for adoption in the US healthcare sector. Echo IQ has also appointed Sam Dribin as CTO to enhance US integrations and product development, and is planning a listing on the OTCQB to increase investor awareness.
EchoIQ Limited has announced a proposed issue of securities, specifically 1,500,000 options expiring on March 4, 2028, with an exercise price of $0.35. This move is part of a placement or other type of issue, with the proposed issue date set for March 4, 2025. The announcement reflects the company’s strategic efforts to potentially enhance its financial position and market presence, although specific implications for stakeholders or industry positioning were not detailed.
EchoIQ Limited has released its consolidated interim financial report for the period ending December 31, 2024. The report includes various financial statements and declarations, providing a comprehensive overview of the company’s financial position and performance. This release is crucial for stakeholders as it offers insights into the company’s financial health and operational efficiency, which can impact its industry positioning and future strategic decisions.
Echo IQ Limited reported a significant increase in revenues from ordinary activities, rising by 533.8% to $101,409 for the half-year ended December 31, 2024. Despite this revenue growth, the company experienced a substantial increase in its loss after tax, which rose by 125.4% to $6,215,645, compared to the previous period. This financial performance indicates a challenging period for the company, with no dividends declared, impacting stakeholders’ expectations.
Echo IQ has received $1.26 million under the Australian Government’s R&D Tax Incentive Scheme for the fiscal year ending June 30, 2024. This funding recognizes the company’s investment in R&D for AI innovations and decision-support solutions for detecting structural heart disease, supporting its operational growth and industry positioning.